Creating sustainable value and advancing human development via sound business principles

BGMS home hero
BGMS home hero

About Bio Green Med Solution, Inc.

Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc.) is a diversified company engaged in both the fire protection and biopharmaceutical industries. Building on its legacy in pharmaceutical research and development, we have expanded our business portfolio through the integration of Fitters Sdn. Bhd., a Malaysia-based group specializing in fire protection products and services. Headquartered in Malaysia, Bio Green Med Solution, Inc. is focused on advancing opportunities across these distinct sectors while maintaining its commitment to driving long-term value creation for shareholders.

Who We Are

Fire Safety

Our Fire Safety division now incorporates Fitters Sdn. Bhd. a Malaysia headquartered company specializing in supplying, and trading various protective and fire safety equipment to both domestic and international markets. Established in 1982, the company has built a strong presence in the industry, providing a wide range of fire safety products, including Fire Equipment, Foam System, Fire Resistant Doors, Personal Protective Equipment (PPE) and Fire Safety Apparel.

Visit Our Fire Safety Division

Biopharmaceuticals

We are a clinical-stage biopharmaceutical company working to develop innovative cancer medicines based on cell cycle, epigenetics and mitosis biology. We are a pioneer company in the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival.

Explore Our Science

Press Releases

Check out the latest news.

View All News

Resources

Access the latest publications.

Apr 2017

Moureau S et al., Identification of pharmacodynamic markers, sensitive target indications and potential combinations. Proc. Ann. Meeting AACR, 2017, Apr 1-5; Washington, D.C., Abstract 4178.

Download PDF

Dec 2016

Moureau S et al., Therapeutic potential of novel PLK1 inhibitor CYC140 in esophageal cancer and acute leukemia. 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics; 2016 Nov 29–Dec 2; Munich, Germany. Abstract 355.

Download PDF
View All Resources

Interested in Learning More About Bio Green Med Solution, Inc.?

Contact Us
woman smiling

Paul McBarron

Executive Vice President, Chief Financial Officer & Chief Operating Officer​

Mr. McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001, as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and served on the Scottish Lifesciences Association Board.